Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Yeah twice a year after the reverse split..LMAO
Want to make some real money. Lets bet on how long it takes this scam to get to .0001
Maybe you are Keith also. lol. Ooooo. Get a grip people.
Dude I know one of these guys personally. Believe me you are barking up the wrong tree. Frankly you are starting to sound a little Looney.
pumpkiller911 and profitmaker69 are not Houlihan what are you talking about? They've been bashing him for years
Oops sub-penny levels again. Look for another Reverse split announcement soon. Just a matter of time.
Don't buy this scam stock. Reverse splits over and over leaving you with nothing
In @ 31.00 pre-market and in the green already. Love this stock. I hope this movement lasts for awhile
My Streamer which is Quotetracker (with TD Ameritrade data)and Scottrade are giving me two different bid/ask prices. So far I was able to buy at the ask Quoteracker is showing. So I guess Scottrade is on another planet as usual.
This stock is a gold mine right now. I would trade it right now as much as possible but wouldn't bet the house on it. It can't move like this forever. One bad article, SEC or whomever steps in and it may be over. Or maybe Martin himself does something to cause it to fall again so he can buy cheaper shares again.I wouldn't put anything past this guy at this point.
NovoCure reports Q3 EPS ($2.09) vs ($1.45) year ago; revs 104.7% y/y to $8.953 mln (no estimates)http://finance.yahoo.com/news/inplay-briefing-com-055139997.html#nvcr
U.S. FDA Approves BELBUCAâ„¢ (buprenorphine) Buccal Film for Chronic Pain Management http://finance.yahoo.com/news/u-fda-approves-belbuca-buprenorphine-100000839.html
Approved see @investor666 on twitter
Please it went up the same day that came out. Does anybody listens to ANALysts anymore? Their price targets are downright comical.
Where is the bottom is the million dollar question. I thought we reached 2 days ago but Bios have had two bloody red days. It should start moving up tomorrow IMO.
Brian K Hall @Investor666 · 11h 11 hours ago
$PBMD-Prima BioMed joins DBI to commercialize iCAN
MAY 25 2015 - 11:12 AM http://www.medifydaily.com.au/prima-biomed-joins-dbi-to-commercialize-ican/ …
0 retweets 2 favorites
And what news might that be. Did I miss something?
Already up to 10.40 pre-market. This stock is unbelievable. A daytraders dream come true
Current Report Filing (8-k)
http://ih.advfn.com/p.php?pid=nmona&article=66915781&symbol=CBYL
Yes I may have to get into this again. Still needs some volume coming in however.
PlasmaTech Biopharmaceuticals Announces Completion of Sanfilippo Syndrome (MPS IIIB) Toxicology Studies at American Society of Gene and Cell Therapy Annual Meeting
NEW ORLEANS, LA--(Marketwired - May 14, 2015) -
Preclinical Studies Support Strong Safety Profile and Investigational New Drug (Ind) Application Filing for Treating Sanfilippo Syndrome (Mucopolysaccharidosis Iiib), a Rare, Fatal Autosomal Recessive Neurodegenerative Disorder
Clinical Studies Planned to Commence in 2015
PlasmaTech Biopharmaceuticals, Inc. (PTBI), a biopharmaceutical company focused on gene therapy and cell therapy products for severe and life-threatening rare diseases announced today that IND enabling safety study data utilizing their adeno-associated virus (AAV9) gene therapy product was presented at the annual meeting of the American Society for Gene and Cell Therapy. The company recently announced its acquisition of Abeona Therapeutics, which has been developing AAV gene therapies for the treatment of Sanfilippo syndromes (MPS IIIA and MPS IIIB).
Sanfilippo syndrome is an inherited genetic disorder that affects children. Children born with Sanfilippo syndrome experience progressive intellectual and motor disability, speech difficulties, seizures, and premature death. As yet, there are no treatments available that can halt or reverse the symptoms of Sanfilippo syndrome.
"These preclinical studies demonstrate increased enzyme levels in target tissues, a strong safety profile, and support our planned clinical trials," stated Tim Miller, Ph.D., President & CEO of Abeona, and prospective CEO of the combined companies upon closing of the transaction.
About Sanfilippo syndrome (Mucopolysaccharidosis IIIB, MPS IIIB):
Sanfilippo syndrome is a group of 4 deadly genetic diseases resulting from the body's inability to properly break down certain sugars. In the class of lysosomal storage diseases, symptoms often appear in the first year of life, and the disease causes progressive muscular and cognitive decline in children after the age of two. Children afflicted with Sanfilippo syndrome experience progressive loss of speech, the ability to eat and walk, and rarely live past their second decade of life. There is no cure and currently no approved treatments for Sanfilippo syndrome.
MPS IIIB is a progressive neuromuscular disease with profound CNS involvement. In this condition, a build-up of a substance called glycosaminoglycans (GAGs) occurs in the lysosomes of cells, particularly in the central nervous system. This is directly related to the malfunction of the a-N-acetylglucosaminidase (NaGlu) enzyme, resulting in dramatic loss of intellectual ability, and a high premature death.
No FDA-approved treatment is currently available for this devastating disorder. Pre-clinical studies using a single intravenous injection of ABX-B (also known as rAAV9.CMV.hNAGLU), have demonstrated restoration of NaGlu activity and corrected the lysosomal storage pathology (histopathology and GAG content) throughout the CNS and in widespread somatic organs. Importantly, intravenous gene delivery of ABX-B improved cognitive and motor functions and normalized the survival of IIIB mice.
Either way I'm good. I'm looking to pick up some cheaper shares
PlasmaTech Biopharmaceuticals Announces Appointment of Todd Wider, MD to Board of Directors
DALLAS, TX and NEW YORK, NY--(Marketwired - May 12, 2015) - PlasmaTech Biopharmaceuticals, Inc. ("PlasmaTech" or the "Company") (PTBI), a biopharmaceutical company focused on advancing cell therapy and gene therapy for rare diseases, announced today that Todd Wider, MD has been elected to the Company's Board of Directors. Dr. Wider has a strong medical background and significant experience in small and mid-cap biotechnology companies.
"We are extremely pleased to be able to add Todd to our board of directors," said Steven H. Rouhandeh, the Company's Executive Chairman. "Todd brings to the board a unique blend of skills and experience that will be of great value to the Company as we continue to build out our product pipeline in cell and gene therapies focused on rare diseases."
Todd Wider graduated with high honors from Princeton University, and earned his MD from Columbia College of Physicians and Surgeons. In addition to his surgical experience, Dr. Wider has extensive experience in the biotechnology investment community and has been a consultant to leading healthcare institutional investors for years. His experience includes public and private financings, corporate development and licensing transactions in the biotechnology and medical device industries.
It's going to hit $12 anyway today. Screw PM Trading
Yes it's on the NASDAQ site. I have TD Ameritrade which explains a lot.
http://www.nasdaq.com/symbol/ptbi/premarket?page=2
I don't see that on my streamer. I'll check the nasdaq site.
Hit a high of 10.17 pre-market and now it's falling fast. Looks like another see saw day. Get ready!
Anthera Pharmaceuticals Reports 2015 First Quarter and Operational Update
Completed Interim Analysis from Phase 3 Trial with Blisibimod for Systematic Lupus Erythematosus
Completed Interim Analysis from Phase 2/3 Trial with Blisibimod for IgA Nephropathy
Increased Cash Position by $43 Million Through Equity Investment by Zenyaku and Equity Offering
Received $3 Million Research Award from Cystic Fibrosis Foundation Therapeutics for Phase 3 Development of Sollpura (liprotamase)
HAYWARD, Calif., May 11, 2015 (GLOBE NEWSWIRE) -- Anthera Pharmaceuticals, Inc. (ANTH) today announced financial results and an operational update for the first quarter ended March 31, 2015.
Net loss for the quarter ended March 31, 2015 was $7.7 million, compared to $7.9 million for the same period in 2014.
Research and development expense for the quarter ended March 31, 2015 was $6.0 million, compared to $5.8 million for the same period in 2014. The increase in research and development expense was primarily due to expansion activities for our BRIGHT-SC IgA nephropathy study and manufacturing activities for our upcoming Phase 3 SOLUTION study with liprotamase.
General and administrative expense for the quarter ended March 31, 2015 was $1.9 million, compared to $1.8 million for the same period in 2014.
Non-operating expense for the quarter ended March 31, 2015 was reduced from $0.3 million to $3,000 mainly as a result of a reduction in interest expense driven by our elimination of all debt financing arrangements in the fourth quarter of 2014.
As of March 31, 2015, we had cash and cash equivalents of $41.6 million, compared to $2.6 million as of December 31, 2014. The increase in our cash balance was mainly driven by total financing proceeds of $45.5 million received from the sale of our common stock through a public offering for $26.9 million, $11.6 million from the sale of common stock through an at-the-market offering and $7.0 million from an equity investment by our collaborative partner, Zenyaku, in the first quarter of 2015.
First Quarter Operational Update:
Sollpura(TM) (liprotamase)
Manufacturing activities for liprotamase progressed on schedule with respect to both capsule and sachet products. Sachet formulation development was substantially completed and pilot-scale feasibility was executed demonstrating manufacturability.
In March 2015, we received a research award from Cystic Fibrosis Foundation Therapeutics Inc. of up to $3 million to support the manufacturing and clinical development of our novel pancreatic enzyme replacement therapy, Sollpura(TM) (liprotamase). Cystic Fibrosis Foundation Therapeutics is a non-profit affiliate of the Cystic Fibrosis Foundation which supports and governs activities related to cystic fibrosis drug discovery through the many stages of drug development and clinical evaluation.
Blisibimod -- Systemic Lupus Erythematosus
In February 2015, we modified the primary efficacy endpoint of CHABLIS-SC1 from the SRI-8 responder index to SRI-6 (previously a secondary endpoint of the study). The SRI (SLE Responder Index) is a recognized endpoint by the FDA for previously approved therapeutics. The change in primary efficacy endpoint was based on our Scientific Advisory Board's evaluation of published clinical data from other recent lupus studies with BAFF inhibitors in which the outcomes as measured using SRI-6 endpoint were more consistent. Subsequent to the amendment of the primary endpoint, an independent un-blinded statistician conducted an interim analysis of CHABLIS-SC1 based on the proportion of responders to the SRI-6 at a pre-specified time point. Based on this analysis, the un-blinded statistician recommended the study to continue to completion as planned. We anticipate full enrollment of 400 patients in the CHABLIS-SC1 trial to be completed this year with top-line efficacy data expected in the second half of 2016.
Blisibimod -- IgA Nephropathy
In March 2015, an interim analysis of the BRIGHT-SC study was conducted by an independent un-blinded statistician, who evaluated several important biomarkers of renal disease in IgA nephropathy amongst patients who had completed at least 8 weeks of treatment. Based on the results of the interim analysis, it was recommended that the BRIGHT-SC trial should continue to completion. Following this outcome, in collaboration with our partner Zenyaku, we are expanding the number of BRIGHT-SC worldwide clinical sites.
I just missed buying at 7.40. I hesitated and then it took off.
Looking good pre-market @ 7.95
You can also email him and ask him to add a stock to his list. I did this with ANTH after I found out about an Insider buy. It was trading around 1.45 then and hit a recent high of 6.50.
Here is a great site for Biotechs including all Phases through PDUFA
http://www.biopharmcatalyst.com/clinical-database/
You can find a lot getting ready to take off here.
This is true. You never know when a Biotech is going to take off.
Yes I tried spreading the word on this one but no one cared.
Moving up nicely from it's pre-market low of 6.70. Already at 7.47. Somebody wants in. This isn't dead yet. Plenty of money still to be made
It's 9.17 and at 10.23 so no 9.50
Doesn't look like she wants to settle. Low of 8.70 and high of 11.50 is my prediction for the day. I'm low-balling the high. lol
Already @ 9.50 pre-market. I think he is on the wrong board and doesn't know it. lol
Looking good pre-market